Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and technology officer at Bristol Myers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

UCB’s anti-tau Alzheimer’s program fails Phase 2 primary endpoint, but highlights positive secondaries

UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint. Neither the low dose nor

November 1, 2024

AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients – Biotech Investments

EQS-News: AiCuris Anti-infective Cures AG / Key word(s): Strategic Company Decision AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

July 7, 2023

‘Conscience’ bills let medical providers opt out of providing a wide range of care

A new Montana law will provide sweeping legal protections to health care practitioners who refuse to prescribe marijuana or participate in procedures and treatments such

August 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.